Castle Biosciences, Inc.

NASDAQ:CSTL

31.8 (USD) • At close November 13, 2024
Bedrijfsnaam Castle Biosciences, Inc.
Symbool CSTL
Munteenheid USD
Prijs 31.8
Beurswaarde 890,632,140
Dividendpercentage 0%
52-weken bereik 16.965 - 35.84
Industrie Diagnostics & Research
Sector Healthcare
CEO Mr. Derek J. Maetzold
Website https://castlebiosciences.com

An error occurred while fetching data.

Over Castle Biosciences, Inc.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary

Vergelijkbare Aandelen

Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

FHTX

8.85 USD

Sangamo Therapeutics, Inc. logo

Sangamo Therapeutics, Inc.

SGMO

2.44 USD

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

32.8 USD

Bioventus Inc. logo

Bioventus Inc.

BVS

11.16 USD

Surmodics, Inc. logo

Surmodics, Inc.

SRDX

38.17 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)